Monensin (sodium)

Monensin (Monensin A) sodium, an orally active antibiotic, is an ionophore that mediates Na+/H+ exchange. Monensin sodium is a potent Wnt signaling inhibitor. Monensin sodium causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin sodium can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects[1][2][3][4].

OC[C@@]1(O)[C@H](C)C[C@H](C)[C@]([C@@]2(O[C@]([C@@]3(CC[C@@]([C@]4(O[C@@]5(C[C@H](O)[C@@H](C)[C@@]([H])([C@H]([C@@H](OC)[C@H](C)C(O[Na])=O)C)O5)CC4)C)([H])O3)CC)([H])[C@@H](C)C2)[H])([H])O1

[1]Dayekh K, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther. 2014 Nov;13(11):2559-71.|[2]Tumova L, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther. 2014 Apr;13(4):812-22.|[3]Youhua Huang, et al. Autophagy Participates in Lysosomal Vacuolation-Mediated Cell Death in RGNNV-Infected Cells. Front Microbiol. 2020 Apr 30:11:790. |[4]Ariel Savina, et al. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic. 2005 Feb;6(2):131-43.bioRxiv. 2023 Jun 25.|bioRxiv. 2023 Sep 12.|bioRxiv. 2024 Jul 27:2024.07.25.605164.|Front Microbiol. 2020 Apr 30;11:790.|Int Immunopharmacol. 2023 Sep 1;124(Pt A):110865.|J Exp Med. 2023 Mar 6;220(3):e20221316.|Nat Commun. 2022 Jul 22;13(1):4255.|Research Square Preprint. 2023 Aug 31.|AAPS PharmSciTech. 2023 Feb 15;24(2):69.|Biochem Pharmacol. 2023 Dec 2:115957.|Clin Exp Immunol. 2023 Dec 26:uxad137.|Clin Immunol. 2022: 109217.|Int J Parasitol Drugs Drug Resist. 2023 Aug, 22, 44-51.|J Exp Clin Cancer Res. 2021 Jan 6;40(1):16.|Nat Methods. 2023 Dec 4.|OncoImmunology. 2023 Apr 19.|Redox Biol. 2022 Aug 27;56:102456.|Signal Transduct Target Ther. 2023 Jul 17;8(1):273.|Small. 2021 Nov 1;e2103984.